ロード中...
Inactivation of the Prolyl Isomerase Pin1 Sensitizes BRCA1-Proficient Breast Cancer to PARP Inhibition
PARP inhibitor monotherapies are effective to treat patients with breast, ovary, prostate, and pancreatic cancer with BRCA1 mutations, but not to the much more frequent BRCA wild-type cancers. Searching for strategies that would extend the use of PARP inhibitors to BRCA1-proficient tumors, we found...
保存先:
| 出版年: | Cancer Res |
|---|---|
| 主要な著者: | , , , , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7755124/ https://ncbi.nlm.nih.gov/pubmed/32193285 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-19-2739 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|